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Mutations in the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene cause CF. The most
common mutation, F508 deletion, causes CFTR
misfolding and endoplasmic reticulum retention, pre-
venting it from trafficking to the cell surface. One
approach to CF treatment is to identify compounds
that correct the trafficking defect. We screened
a marine extract collection and, after extract, decon-
volution identified the latonduines as F508del-CFTR
trafficking correctors that give functional correction
in vivo. Using a biotinylated azido derivative of
latonduine, we identified the poly(ADP-ribose) poly-
merase (PARP) family as latonduine target proteins.
We show that latonduine binds to PARPs 1, 2, 3, 4,
5a, and 5b and inhibits PARP activity, especially
PARP-3. Thus, latonduine corrects F508del-CFTR
trafficking by modulating PARP activity. Latonduines
represent pharmacologic agents for F508del-CFTR
correction, and PARP-3 is a pathway for the develop-
ment of CF treatments.
INTRODUCTION
Cystic fibrosis (CF) is the most common lethal genetic disease
that affects caucasians. It is caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR), the
primary chloride channel in the apical membrane of epithelial
cells (Riordan et al., 1989). Deletion of a phenylalanine at position
508 (F508del-CFTR) is the most common mutation, being
present on at least one chromosome in approximately 90% of
CF patients (Cheng et al., 1990). The F508del-CFTR mutation
disrupts proper CFTR protein folding, trafficking to the plasma
membrane, stability in the plasma membrane, and channel
gating (Lukacs et al., 1993; Hwang and Sheppard, 2009).
F508del-CFTR heterozygotes express about 50% of the wild-
type protein level at the cell surface and display no disease1288 Chemistry & Biology 19, 1288–1299, October 26, 2012 ª2012 Ephenotype (Gabriel et al., 1994). Estimates suggest that thera-
peutic benefits could be gained if only a fraction of the endo-
plasmic reticulum (ER)-retained F508del-CFTR were rescued.
These estimates range from 10% to 25%ofwild-type expression
(Farmen et al., 2005; Zhang et al., 2009). Thus, therapies that
partially rescue F508del-CFTR retention may be beneficial.
F508del-CFTR trafficking in cultured cells can be rescued by
incubating the cells at lower temperatures, resulting in a partially
functional Cl channel (Denning et al., 1992). A diverse group of
‘‘corrector’’ compounds have been reported to rescue F508del-
CFTR function, includingglycerol (Satoet al., 1996), sodiumphenyl
butyrate (Rubenstein et al., 1997), curcumin (Egan et al., 2004), the
phosphodiesterase 5 inhibitors sildenafil (Dormer et al., 2005) and
KM11060 (Carlile et al., 2007), miglustat (Norez et al., 2006), the
analgesic glafenine (Robert et al., 2008, 2010), as well as VRT325
(Loo et al., 2005) and VX809 (Van Goor et al., 2011; Clancy et al.,
2012). Recently, sets of mutations in and around nucleotide
binding domain 1 (NBD-1) have been identified that correct the
misfolding and mislocalization of F508del-CFTR. These muta-
tions suggest that two separate flaws in CFTR folding need to
be corrected for significant rescue to occur (Rabeh et al., 2012).
Despite these efforts to identify drugs that rescue F508del-
CFTR trafficking, only a few have progressed successfully into
leads (Robert et al., 2010). To date, the only corrector drugs to
have reachedclinical trials areVX809,whichhasenteredphase3,
and sildenafil, which is in phase 2 as an anti-inflammatory
(Van Goor et al., 2011; Cystic Fibrosis Foundation). This may
be due to the use of combichem-generated compound libraries
for screening. These commercial libraries typically encompass
limited chemical space when compared with natural com-
pounds. To diversify the collection of corrector compounds, we
have screened extract libraries derived from Pacific marine
sponge extracts (Paleari et al., 2006). The marine environment
has been shown to be a rich source of structurally novel bioactive
secondary metabolites, with sponges being the most prolific
marine source of newly reported natural products (Sipkema
et al., 2005). We screened a marine extract collection using
bioassay-guided fractionation and identified the chemically
synthesizable latonduines as potent correctors of F508del-
CFTR misfolding. Latonduine treatment corrects F508del-CFTRlsevier Ltd All rights reserved
Figure 1. Latonduines: A Group of CFTR
Trafficking Correctors
(A) Latonduine structures.
(B) Changes in CFTR surface expression (F508del-
CFTR [F508del] and wild-type) in BHK cells with
latonduine A treatment (24 hr) (1 mM). Parental
BHK shows level of staining without constitutively
expressed CFTR, and secondary antibody shows
the staining present without the primary anti-HA
antibody.
(C) Immunoblot of latonduine A-treated (Lat A)
(10 mM) BHK cells for 24 hr for the presence of
CFTR and tubulin (wt, wild-type CFTR; c, mock-
treated F508del-CFTR). Tubulin immunoblot
demonstrates equal protein loading.
(D) Densitometry of the immunoblot in (C) to
determine the relative amounts of bands B and C
in each lane.
(E) Immunoblot of latonduine A-treated (1 mM)
CFBE cells expressing F508del-CFTR. Tubulin
immunoblot demonstrates equal protein loading.
(F) Densitometry of the immunoblot in (D) to
determine the relative amounts of bands B and C.
All data are presented as mean ± SEM. All
experiments were completed in triplicate.
See also Figure S8.
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Latonduine Corrects F508del-CFTR via PARPtrafficking up to 45% of wild-type CFTR surface expression, as
monitored by confocal microscopy. Halide efflux assays in both
baby hamster kidney (BHK) and CFBE41o cells further demon-
strated that latonduine correction results in functional cell-
surface F508del-CFTR. This result was confirmed in F508del-
CFTR mice in both ex vivo and in vivo studies. Using pull-down
studies with both a biotinylated latonduine and an azido-
latonduine, we identified via mass spectrometry poly(ADP-
ribose) polymerase 1 (PARP-1) as a target protein for latonduine.
We show that latonduine binds not only to PARP-1 but also to
PARPs 2, 3, 4, 5a, and 5b. Upon testing, we found that latonduine
was a weak PARP inhibitor for all the PARPs tested except
PARP-3, for which it is very strong (ED50 400 pM). Further, we
show that reducing PARP-3 expression in cells reduced the
amount of latonduine needed for peak F508del-CFTR correction.Chemistry & Biology 19, 1288–1299, October 26, 2012 ªWe show that increasing the PARP
activity level counteracts the corrective
action of latonduine, hence showing that
latonduines function as correctors by
modulating PARP activity, in particular
PARP-3. Latonduine thus represents,
to our knowledge, a new class of poten-
tial CF therapeutics, and the PARP
family represents a potentially novel
target protein group for future CF drug
development.
RESULTS
Marine Sponge-Derived
Latonduines Correct F508del-
CFTR Trafficking
Using a cell-based assay-guided frac-
tionation of 720 marine extracts derivedfrom South Pacific sponges, we identified a class of compounds
known as the latonduines (Figures 1A and 1B). The results show
that all three latonduines, in particular latonduine A, trigger signif-
icant surface expression of F508del-CFTR but not wild-type
CFTR, except latonduine B (ethyl). The parental BHK response
showed that the signal was due to the stably transfected CFTR
and not endogenous protein.
Latonduine Causes Mature Glycosylation
in F508del-CFTR
In the ER, CFTR acquires core glycosylation and appears on
immunoblots as a distinct band (band B). In the Golgi, additional
CFTR glycosylation occurs and a higher molecular weight band
C form appears (Carlile et al., 2007). Hence, immunoblotting can
effectively determinewhether CFTR has trafficked from the ER to2012 Elsevier Ltd All rights reserved 1289
Figure 2. Validation of the Latonduines
(A) BHK cells latonduine treated (1 mM) for 24 hr and
probed with wheat germ agglutinin (red) and CFTR
(green). Orange indicates areas of colocalization,
some of which are highlighted by the arrowheads.
All scale bars represent 50 mm. (a and b) BHK cells
probed only with secondary antibody. (c and d)
Cells expressing CFTR probed with WGA and
antibody to CFTR. (e) Cells expressing CFTR pro-
bed with an antibody of the same isotype that does
not bind CFTR and WGA. (f–h) BHK cells treated
with the latonduines and probed with WGA and
anti-CFTR antibody.
(B) Surface CFTR is quantified by measuring the
number of pixels of overlap. Data are presented as
mean ± SEM. All experiments were completed in
triplicate, and significance was tested by paired
t test. *p < 0.05; ***p < 0.001.
(C) Concentration gradient in the BHK HTS assay
for latonduine A treatment after 24 hr.
(D) Time course of the BHK HTS assay with
latonduine A (1 mM). All data are presented as
mean ± SEM. All experiments in this figure were
completed in triplicate.
Chemistry & Biology
Latonduine Corrects F508del-CFTR via PARPthe Golgi. Latonduine A treatment corrects F508del-CFTR pro-
cessing in BHK cells and increases band C expression to about
70%of that observed for wild-type CFTR (Figures 1C and 1D). To
confirm band C generation in a more physiologically relevant
system, CFBE41o cells, a human epithelial cell line derived
from an F508del-CFTR CF patient, were treated with latonduine
A (1 mM). Treatment produced 25% correction after 48 hr, as
monitored by immunoblotting (Figures 1E and 1F). Thus, laton-
duine A rescues F508del-CFTR misfolding to a therapeutic level
by correcting trafficking through normal biosynthetic pathways.
Visualizing Latonduine Correction
To visualize the correction of F508del-CFTR (no HA tag), BHK
cells expressing F508del-CFTR were treated with latonduine
(10 mM) for 24 hr, immunostained for CFTR, and imaged by
confocal microscopy (Figure 2A). Images in Figures 2Aa–2Ae
are controls; they show first that secondary antibodies alone
do not give fluorescence (Figures 2Aa and 2Ab), second that
no surface CFTR signal is visible in the untreated F508del-
CFTR cells, unlike the wild-type CFTR surface signal (Figure 2Ac
and 2Ad), and by the use of a nonspecific control antibody of the
same isotype as the CFTR antibody (Figure 2Ae) that the staining
seen in Figures 2Af–2Ah is CFTR. All three forms of latonduine
triggered surface CFTR expression (Figures 2Af–2Ah) (white
arrows). The amount of surface CFTR staining overlap with the
cell-surface marker wheat germ agglutinin (WGA) wasmonitored
for 200 cells per treatment (Figure 2B). Using the ImageJ
program, only the cell surface marked by WGA was measured.
Each pixel in the cell-surface image was designated to show
overlap or not, and hence a score was generated for each cell.1290 Chemistry & Biology 19, 1288–1299, October 26, 2012 ª2012 Elsevier Ltd All rights reWGA also shows staining on some internal
membranes; this is due to the cells being
partially permeabilized to allow access
for the CFTR antibody to bind its cyto-
plasmic epitope. Latonduine A and laton-duine B treatment resulted in F508del-CFTR trafficking to the
cell surface, producing 48% and 51% of the surface wild-type
CFTR signal, respectively. This is significantly more rescue
than is believed to be required for a therapeutic benefit.
Latonduine A was selected for further analysis due to its ability
to dramatically increase F508del-CFTR rescue without affecting
the trafficking of wild-type CFTR (Figure 1B). Latonduine A EC50
of 1 nM was determined using the high-throughput screen (HTS)
assay at a range of concentrations (Figure 2C). Latonduine A
treatment resulted in a significant correction at concentrations
down to 1 nM. Latonduine A gave a decrease in CFTR signal
at 100 mM, indicating a toxic effect at higher concentrations.
However, this response has been observed in this assay previ-
ously and may be a system artifact, as latonduine A treatment
had little effect on wild-type CFTR trafficking at all concentra-
tions tested.
To understand the dynamics of F508del-CFTR correction, we
used the HTS assay to perform a time course for latonduine A
(1 mM) (Figure 2D). No correction occurred before 6 hr of
treatment. At 6 hr an increase in cell-surface signal was
detected, but this only became significant at 18 hr. The surface
CFTR signal peaked at 48 hr, remaining significant until
after 72 hr. Hence, from one dose almost 60 hr of increased
surface F508del-CFTR was obtained, but this needed 18 hr to
appear.
Latonduine Functionally Corrects F508del-CFTR in
Human Cell Lines and in an In Vivo Mouse Model
For any therapeutic benefit, the corrected F508del-CFTR must
be functional. We tested whether the corrected CFTR couldserved
Figure 3. Functionality of Latonduine-
Rescued CFTR
(A and B) Halide efflux assay of latonduine
A-treated (10 mM) F508del-CFTR-expressing BHK
cells. The F508del-CFTR control is vehicle (DMSO)
treatment. Cells are stimulated at time 0 with
10 mM forskolin and 50 mM genistein (SEM; n = 3).
(C) Latonduine A concentration gradient (24 hr)
detected by halide efflux.
(D) Latonduine A treatment monitored over time
course by iodide efflux in BHK cells.
(E) Halide efflux of latonduine A (10 mM) (24 hr)
treatment in human lung epithelial cells from
a cystic fibrosis patient that express F508del-
CFTR (CFBE41o).
(F and G) Latonduine A effects on CFTR
functionality in F508del-CFTR homozygous mice
or wild-type littermates. (F) Ussing chamber-
mounted mouse ileum was measured for Isc
response at time 0 and then treated with
latonduine (10 mM) in DMSO or DMSO alone for
4 hr. The Isc response to forskolin + genistein was
then measured again (SEM of five pieces of ileum
per mouse from six mice). (G) F508del-CFTR
functional rescue measured in vivo by murine
salivary secretion. Mice were treated with la-
tonduine A (48 hr) at 0.25 mg/kg/day and then
stimulated to secret saliva (30 min), and the
amount was measured. Data are presented as
mean ± SEM (n = 5 for each). *p < 0.05; **p < 0.01;
***p < 0.001.
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Latonduine Corrects F508del-CFTR via PARPform ion channels that function in halide efflux assays (Figures 3A
and 3B). Briefly, cells that have been treated with a corrector will
express cell-surface F508del-CFTR. The cells are then loaded
with iodide (chloride mimic), washed, and stimulated to release
iodide, which is detected by an iodide electrode. Only cells
with functional surface CFTR can do this. Latonduine-treated
(1 mM for 24 hr) BHK cells gave significantly more functional
F508del-CFTR (42-fold) than the vehicle-treated controls
(DMSO). In comparison, wild-type CFTR function was 81-fold
greater than the same controls. In conclusion, latonduine A
triggers F508del-CFTR rescue, and the corrected CFTR is
functional.
Next, to determine latonduine correction dynamics, we per-
formed a time course and concentration gradient for halide
efflux (Figures 3C and 3D). As with the surface-expression
results in Figures 2C and 2D, latonduine treatment produced
significant levels of halide efflux at concentrations between
1 nM and 100 mM after 24 hr of treatment (Figure 3C). Interest-
ingly, unlike the screen assay (Figure 2D), significant efflux isChemistry & Biology 19, 1288–1299, October 26, 2012 ªdetectable after only 6 hr of treatment,
with peak halide efflux occurring after
48 hr (Figure 3D). We also performed
halide efflux on latonduine A-treated
CFBE41o cells expressing F508del-
CFTR. These showed a 31-fold in-
crease in functional F508del-CFTR signal
(Figure 3E). Thus, latonduine treat-
ment results in the functional correction
of F508del-CFTR ion channels acrossa range of concentrations, and this is sustained for several
days.
To establish the ability of latonduine to correct F508del-CFTR
ex vivo, it was tested on isolated intestinal ileal epithelia from
F508del-CFTR homozygous mice (French et al., 1996). The
epithelial strips were incubated with 10 mM latonduine for 4 hr
and CFTR channel activity was measured with an Ussing
chamber (Figure 3F). Latonduine treatment gave a small but
significant increase (2.5% of wild-type littermates) in CFTR
activity over controls.
To determine the ability of latonduine A to correct CFTR in vivo,
it was tested using a salivary secretion assay in F508del-CFTR
homozygous mice (Figure 3G; Best and Quinton, 2005). Mice
were fed with 50 mg/kg latonduine A by gavage once daily for
2 days. After stimulation, the maximum rate of latonduine-
treated CF mice saliva production was 9% of WT. In contrast,
vehicle-treated mice were only 0.12% of that in wild-type litter-
mates (Figure 3G). Thus, latonduine A corrects F508del-CFTR
in whole animals potentially at therapeutically useful levels.2012 Elsevier Ltd All rights reserved 1291
Figure 4. Latonduine Does Not Rescue
F508del-CFTR through CFTR Transcription
or Translation
(A) Real-time quantitative PCR quantitation of
CFTR expression in CFBE41o cells expressing
F508del-CFTR treated with 10 mM latonduine for
48 hr. Data were normalized to GAPDH and
experiments were performed in triplicate.
(B) BHK cells expressing F508del-CFTR were
treated with latonduine (10 mM) or simultaneously
with latonduine and cycloheximide (5 mg/ml) for
24 hr and monitored in the HTS assay. All data are
presented as mean ± SEM (n = 6).
See also Figure S2.
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Latonduine Corrects F508del-CFTR via PARPLatonduine A Corrects F508del-CFTR
Posttranslationally, but Not through Direct Binding
to NBD-1
Previous reports have shown that changes in CFTR transcription
have altered CFTR surface expression (Dalemans et al., 1991).
To determine whether this was true for latonduine A, its effect
on CFTR expressionwasmonitored (Figure 4A). CFBE41o cells
were treated for 24 hr with 1 mM latonduine A, mRNA was iso-
lated, and real-time RT-PCR was performed. Results show no
significant effect on CFTR gene expression by latonduine treat-
ment, suggesting that CFTR transcription is not involved in
CFTR trafficking. To determine whether latonduine’s rescue
requires protein biosynthesis, latonduine was tested in concert
with cycloheximide in the HTS assay. The result shows that
cycloheximide has no significant effect on rescue, hence sug-
gesting that transcription and translation play little role in
latonduine-mediated rescue (Figure 4B). To determine whether
latonduine directly interacts with the site of the F508 deletion
on CFTR, the direct binding of latonduine to NBD-1 was tested
by differential scanning fluorometry (see Figure S2 available
online). Briefly, this assay determines the ability of compounds
to bind to a particular protein by monitoring for an upward shift
in the said protein’s melting temperature caused by compound
binding. As the protein unfolds, a fluorescent dye with an affinity
for the newly exposed hydrophobic motifs binds to the protein
and changes fluorescence; it is this that ismonitored. Latonduine
even at 100 mM shows no such shift, and hence latonduine does
not bind to NBD-1.
Identification of the Target of Latonduine as the PARP
Protein Family
Given that latonduine did not bind to CFTR NBD-1 directly, we
chose to attempt to identify latonduine target proteins. To do
this, we produced a biotinylated form and subsequently an azido
form of latonduine. A potential modification site appeared to be
the acidic pyrrole NH. An N-methylated pyrrole derivative was
developed and found to demonstrate similar levels of correction
to latonduine in the BHK HTS assay (Figures S3A and S3B).
Further, it gives similar levels of band C in immunoblots from
BHK cells (Figures S3C and S3D), and when tested in halide
efflux assays the methylated latonduine gave a similar level of
functionality to latonduine (Figure S3E). Hence, in short, the
methylated latonduine maintains its biological activity as an1292 Chemistry & Biology 19, 1288–1299, October 26, 2012 ª2012 EF508del-CFTR trafficking corrector (Figure S3), and so this site
was chosen for further modification to create latonduine affinity
reagents (Figures S4–S6).
To identify the latonduine cellular target, we incubated bio-
tinylated latonduine with CFBE41o cell lysates. The identity
of the bound proteins was determined by SDS-PAGE and
trypsinization followed by mass spectrometry. In three separate
experiments the abundant human PARP-1 was isolated (Fig-
ure S1; Tables S1A and S1B). PARP-1 was the only protein
that was reproducibly identified in all three experiments; no other
protein was isolated in even two.
To confirm that latonduine binds directly to PARP-1, we
performed pull-down studies of CFBE cell lysates using bio-
tinylated latonduine A and western blots with anti-PARP-1
antibody (Figure 5A; Figure S1). This was repeated using
recombinant PARP-1 (Figure 5B), confirming that biotinylated
latonduine binds PARP-1 directly.
To identify the latonduine A binding site on PARP-1, bio-
tinylated latonduine was used to pull down recombinant
PARP-1 in the presence of increasing concentrations of known
PARP-1 enzymatic inhibitors PJ-34 and ABT888 (Figure 5C)
(Abdelkarim et al., 2001; Liu et al., 2008). In addition, latonduine
and VRT325 as a control were tested. PARP-1 was used at
10 mM and bio-latonduine at 100 nM; the three concentrations
chosen for the PARP inhibitors were 10 nM, 100 nM, and
1 mM. PARP was preincubated with the inhibitors for 1 hr prior
to bio-latonduine addition. Results show that at higher concen-
trations, latonduine A, ABT888, and PJ-34 block the interaction
between PARP-1 and bio-latonduine but VRT325 does not.
Thus, latonduine A, ABT888, and PJ-34 all bind PARP-1 at the
same site. As ABT888 is an NAD analog that has been shown
by X-ray crystallography to complex with and bind at the NAD
binding site of the catalytic domain of PARP-2 (data from the
Structural Genomics Consortium; http://www.sgc.utoronto.ca),
we can deduce that latonduine binds directly to PARP-1 in the
catalytic domain.
Latonduine Binds PARPs 2, 3, 4, 5a, and 5b Directly
and Inhibits the Enzymatic Activity of All PARPs
To test whether latonduine binds to the PARP-1 catalytic domain
and/or other PARPs (PARPs 2, 3, 4, 5a, and 5b), bio-latonduine
and azido-latonduine pull-downs were undertaken with re-
combinant PARP-1 catalytic domain and the full-length proteinslsevier Ltd All rights reserved
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Figure 5. Bio-Latonduine A Interaction with
PARP FamilyMembers Tested by Pull-Down
Assay
(A) Bio-latonduine pull-down assay on CFBE41o
cells. Cells were lysed, and the lysate was split into
two aliquots; one was incubated (2 hr) with bio-
latonduine linked to streptavidin beads (LAT), and
the other was incubated (2 hr) with biotin-treated
streptavidin beads (CON). After collection and
washing (Last W), samples were subsequently
immunoblotted (Pulldown). Note a similar bio-
tinylated latonduine pull-down experiment was
carried out in order to initially identify PARP by
mass spectrometry (see Figure S1 and Table S1).
(B) Purified recombinant human PARP-1 (1 mg,
Load) was used. PARP-1 was precleared using
beads preincubated with biotin (PC). Recombinant
PARP-1 was then incubated with either beads
preincubatedwith biotin (Beads) or with beads and
biotinylated latonduine (Bio-L).
(C) Biotinylated latonduine (BL) pull-down of re-
combinant PARP-1 in the presence of latonduine
(LAT) and PARP-1 inhibitors (ABT888 and PJ34);
the compound VRT325 (COR-325) was used as
a control. Biotinylated latonduine was used at
1 mM; the other compounds were used at 100 nM,
1 mM, and 10 mM (1, 2, and 3, respectively). Visu-
alized by western blot probed by anti-CFTR
antibody. Recombinant PARP-1 (P-1) biotinylated
bead pull-down (B-1) and final wash (W) were all
run as controls.
(D–J) Pull-down assays using recombinant human
PARP-1 catalytic domain (D), recombinant human
full-length PARP-2 (E), PARP-3 (F), PARP-4 (G),
PARP-5a (H), and PARP-5b (I), and phosphodies-
terase 4D (PDE-4D) (J) as a control. All seven
immunoblots show the last wash (Last W), the
biotinylated latonduine pull-down (Bio-L), and
biotinylated beads only (Beads). Some blots also
show the azido-latonduine pull-down (AZ-L).
See also Figures S3–S6.
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Latonduine Corrects F508del-CFTR via PARPof PARP-2, PARP-3, PARP-4 (vault P193), PARP-5a (tankyrase
1a), and PARP-5b (tankyrase 1b), with recombinant PDE-4D
protein used as a control (Figures 5D–5J). The results show
that latonduine binds to all the PARP proteins and to the
PARP-1 catalytic domain but not to PDE-4D. Although some
PARP-3 is visible being pulled down by biotinylated beads alone,
this ismuch less than that seen pulled down by azido-latonduine.
Given that latonduine binds to all the PARPs tested and in
the catalytic domain, does this mean that it is also a PARP
inhibitor? To establish this, PARP enzymatic activity was tested
in the presence of various latonduine concentrations (Figure 6;
Table S2). Also tested were ABT888 (PARP-1 inhibitor) as well
as VRT325 (CFTR corrector and negative control). Latonduine
acts as a weak PARP inhibitor for many of the PARP family
members tested, with the EC50 always being in the micromolar
range (EC50 for PARP-1 at 50 mM, PARP-2 at 20 mM, PARP-4
at 9 mM, PARP-5a at 90 mM, and PARP-5b at 1 mM). In contrast,
ABT888 is a stronger general PARP inhibitor (EC50 for PARP-1 at
7 nM, PARP-2 at 80 nM, PARP-4 at 9 nM, and PARP-5b at
50 nM). Interestingly, there are two exceptions: these trendsChemistry & Biology 19, 1288–1are the EC50 for ABT888 being 90 mM for PARP-5a, whereas
latonduine A inhibits PARP-3 with an EC50 of 400 pM (ABT888,
EC50 = 300 pM) (Table S2). Hence, in conclusion, latonduine
appears to behave as a weak general PARP inhibitor, but
conversely is a strong inhibitor of PARP-3.
Increasing PARP Activity Counteracts the Corrector
Activity of Latonduine
To determine whether latonduine corrects F508del-CFTR
misfolding via its ability to modulate PARP activity, we used per-
oxynitrite, which has previously been shown to increase PARP
activity (Scott et al., 2004). We treated BHK cells express-
ing F508del-CFTR-3HA with peroxynitrite at concentrations
between 1 mM and 1 mM for 3 hr and then with latonduine
(10 mM) (Figure 7A). Cells were tested for CFTR correction by
our HTS assay. The data showed that latonduine corrector
activity began to decrease at 20 mM peroxynitrite treatment
and disappeared by 100 mM (Figure 7A). The effect of peroxyni-
trite on PARP activity was also tested (Figure 7B). The results
show that latonduine A treatment alone reduced PARP activity299, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1293
Figure 6. Latonduine A Inhibits Multiple
PARPs
(A) Standard curve of human recombinant PARP-1
activity measured by the HT Universal Chemilu-
minescent PARP assay kit (Trevigen). The amount
of PARP used in all subsequent experiments is 0.5
units.
(B–G) Measurement of PARP activity in the
presence of various concentrations of latonduine
and ABT888 with VRT325 at 10 mM and PARP-1
(B), PARP-2 (C), PARP-3 (D), PARP-4 (vault P193)
(E), PARP-5a (tankyrase 1a) (F), and PARP-5b
(tankyrase 1b) (G).
All data are presented as mean ± SEM (n = 6).
See also Table S2.
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Latonduine Corrects F508del-CFTR via PARPby almost 50%. However, upon addition of 20 mM peroxynitrite,
this reduction in PARP activity disappeared. Immunoblotting
confirmed this result: at concentrations of peroxynitrite above
20 mM, latonduine no longer generated band C (Figure 7C).
These results suggest that the corrector activity of latonduine
A operates via PARP inhibition.
siRNA Knockdown of PARP-3 Expression Reduces the
Amount of LatonduineNecessary forMaximumF508del-
CFTR Rescue
To determine whether the ability of latonduine A to correct CFTR
misfolding is linked specifically to PARP-3 inhibition, we used
siRNA to knock down the expression level of PARP-3 and test
whether less latonduine is required for CFTR correction (Fig-
ure 7D). HEK293 cells expressing F508del-CFTR-3HA in a Flp-In
T-REx system (Invitrogen) were used, as siRNA for human cells is
much more readily available than for other animals. They were
grown for 24 hr, transduced with siRNA for PARPs 1, 3, or 5a,1294 Chemistry & Biology 19, 1288–1299, October 26, 2012 ª2012 Elsevier Ltd All rights resand cultured for another 24 hr. Then the
cells were latonduine treated for 24 hr at
varying concentrations (1 mM, 100 nM,
10 nM, and 1 nM) and F508del-CFTR
trafficking to the cell surface was tested.
Results show that PARP-1 and PARP-
5a knockdowns (of at least 60%; Fig-
ure S7) have no significant effect on the
latonduine concentration necessary for
optimal CFTR rescue. However, PARP-3
siRNA knockdown significantly reduces
the amount of latonduine needed to elicit
optimal correction of F508del-CFTR, with
the EC50 of latonduine dropping from
8 nM to 200 pM. Thus, latonduine A acts
to rescue F508del-CFTR directly through
PARP-3 inhibition.
Latonduine Rescues CFTR
Misfolding in Combination with
Other Correctors Including VX809
We hypothesized that treatment with
multiple correctors that act through dif-
ferent pathways could increase thera-
peutic benefit. To address this, we
studied the effect of latonduine treatment in combination with
other correctors using the HTS assay (Figure S8). The
compounds were prior tested in the HTS assay to determine
the optimal concentration to use in the combination assay.
Further, none of the compounds tested in combination with
latonduine showed any PARP activity when tested on their
own (data not shown). The data show that the PDE-5 inhibitors
(sildenafil, vardenafil, tadalafil, and KM11060) do have an addi-
tive effect on F508del-CFTR trafficking in combination with
latonduine A, but not glafenine. The pharmacologic chaperones
(RDR1 and VRT325) that bind directly to the NBD-1 of CFTR
gave differing results. Treatment with RDR1 is not additive,
whereas VRT325 is additive. Finally, VX809 gave an additive
corrector response with latonduine A. Two of these combina-
tions (latonduine + sildenafil and latonduine + VX809) were
then confirmed by immunoblotting (Figure S8B). The immunoblot
was quantified (Figure S8C) and showed that both the levels of
band B and band C increased in the combinations. These resultserved
Figure 7. Latonduine-Mediated F508del-
CFTR Correction Is Modulated by Changes
in PARP Activity
(A) BHK cells expressing F508del-CFTR were
treated with varying peroxynitrite concentrations
(1 mM to 1 mM) and latonduine (10 mM) for 24 hr,
and F508del-CFTR surface expression was
monitored in the HTS assay.
(B) PARP activity in BHK cells treated as in (A) were
monitored using the in vivo pharmacodynamic
assay (Trevigen). BHK cells treated with DMSO
(vehicle) are the control and represent the back-
ground level of PARP activity in the cell.
(C) Immunoblot of BHK cells treated as in (A) and
probed for CFTR and tubulin. Wild-type CFTR is
shown as a control. Tubulin is probed here as
a protein-loading control.
(D) Cell-surface CFTR levels were monitored in
HEK cells expressing F508del-CFTR and treated
with various concentrations of latonduine A (0 nM,
100 pM, 1 nM, 10 nM, 100 nM, 1 mM, 10 mM) in
combination with siRNA knockdown of PARP-1
(green), PARP-3 (red), or PARP-5a (blue). PARPs
were knocked down 24 hr prior to a 24 hr
latonduine treatment. The level of siRNA knock-
down was monitored by quantitative PCR (Fig-
ure S7). The results shown are a representative
experiment performed in triplicate.
All data are presented as mean ± SEM.
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Latonduine Corrects F508del-CFTR via PARPshow that latonduine A, to our knowledge, defines a new
F508del-CFTR corrector pathway acting through PARP-3. In
addition, combined treatment with other correctors acting with
different mechanisms gives increased levels of correction.
Thus, latonduine A and its derivatives after optimization by struc-
ture-activity relationship (SAR) analysismay develop into a viable
therapeutic combination.
DISCUSSION
Correction of ER-retained F508del-CFTR by small molecules is
a promising potential cystic fibrosis therapy. Chemically diverse
corrector molecules have been identified; however, elucidating
their targets and mechanisms of action has been hampered by
their low affinities. In some cases, known compounds such as
phosphodiesterases and histone deacetylases have been iden-
tified (Robert et al., 2008; Hutt et al., 2010). One strategy has
been to search in chemical space for similarity with compounds
of known function (Robert et al., 2008). However, for most
correctors, the target remains unknown. This hampers corrector
development by rational SAR campaigns based on structural
and other information of the target. We describe here a cell-
based F508del-CFTR trafficking screen of marine sponge
extracts for correctors. We deconvolved one of the hit extracts
and identified latonduine A as the active component, with subse-Chemistry & Biology 19, 1288–1299, October 26, 2012 ªquent validation of the F508del-CFTR
functional correction in cells and in vivo
in a mouse CF model. We utilized an
azido biotinylated latonduine derivative
to detect the cellular target as the PARP
family. We show in vivo that peroxyni-trite-mediated PARP induction alters the sensitivity of F508del-
CFTR trafficking to latonduine. We identify PARP-3 as the
most sensitive PARP family member to inhibition by latonduine,
andwith siRNA knockdownswe confirm that this inhibitionmedi-
ates the corrector activity of latonduine in vivo. Thus, we identify,
to our knowledge, a new pathway for secretory protein quality
control and trafficking.
Marine sponges are an excellent source of chemically diverse
bioactive molecules (Sipkema et al., 2005). Latonduine isolation
as the active component in an extract was unexpected, as previ-
ously latonduine has shown no identifiable biological activity or
toxicity (Linington et al., 2003), and thus, to our knowledge,
this is the first description of a biological activity for latonduine.
We show that latonduine binds to PARP family members 1, 2,
3, 4, 5a, and 5b. In some cases this interaction is weak, and
was only detectable with azido-latonduine. Latonduine acts as
a weak inhibitor of PARPs 1, 2, 4, 5a, and 5b, but PARP-3 inhibi-
tion is more potent and equivalent to PARP-1 inhibition by the
known inhibitor ABT888 (Liu et al., 2008) (Figure 6). To confirm
that the inhibition of PARP activity is needed for F508del-CFTR
correction, we increased general PARP activity by peroxynitrite
treatment and show that this reduces latonduine potency (Scott
et al., 2004) (Figure 7). To establish that PARP-3 mediated the
CFTR correction in vivo, we used siRNA knockdowns of
PARP-3 and show that the amount of latonduine required to2012 Elsevier Ltd All rights reserved 1295
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PARP-1 and PARP-5b had no effect on F508del-CFTR traf-
ficking (Figure 7D). Hence, PARP-1, the PARP family member
that we initially detected, is not the prime latonduine target.
Instead, the results prove that the mechanism of action of laton-
duine A is by inhibiting cellular PARP-3 activity (Figure 7).
The results raise the following questions: why did we originally
identify PARP-1 and not PARP-3, and why, despite potentially
similar catalytic domains, does latonduine act as a strong inhib-
itor of PARP-3 and not PARP-1? To address the first point, it may
simply be a consequence of mass spectrometric sensitivity, with
PARP-1 being significantly more abundant in cells than PARP-3.
This situation may have been exacerbated by the possibility that
most PARP-3 is bound in tight nuclear complexes resistant to
solubilization whereas a sizable portion of PARP-1 is located in
the cytoplasm, and hence sample preparation may have biased
mass spectrometry against detecting PARP-3. The difference in
inhibition potency for latonduine between PARPs 1 and 3may be
due to subtle differences in the structure of the catalytic domain
between the two enzymes.
PARP-3 has roles in DNA repair and mitotic progression and is
known to activate PARP-1 in the absence of DNA (Loseva et al.,
2010), indicating that PARP-1 has roles outside of DNA repair.
How it mediates CFTR correction remains unclear (Loseva
et al., 2010). However, recent evidence has appeared for new
roles for PARP family members in modulating intracellular
protein trafficking (Abd Elmageed et al., 2012). Activated
PARP-1 induces transcription factor HMGB1 to traffick from
the nucleus to the cytoplasm, eliciting a potent inflammation
response (Abd Elmageed et al., 2012). Further, PARP-1 has
been shown to act as a chaperone transporting proteins
between chromatin and Cajal bodies in the nucleus (Abd Elma-
geed et al., 2012). Indeed, PARPs canmodulate ABC transporter
activity (Abd Elmageed et al., 2012). UV inactivation of ABC
transporters is PARP-1 dependent, possibly by monomeric
ADP-ribose generation that competes with ATP for ABC trans-
porter binding (Abd Elmageed et al., 2012).
Like other CFTR correctors, for latonduine, although its target
is known, the exact mechanism of action, in other words the
precise cellular target (or targets) of polyADP-ribosylation
responsible for their biological activity, is not. A complete picture
of the latonduine mechanism of action will require a variety of
experimental approaches.
In the PARP-1 and PARP-2 protein interactomes, most
members are involved in DNA maintenance and repair (Isabelle
et al., 2010). However, also identified were the AP-2 complex
and HSP90. These were also identified in biotinylated latonduine
affinity experiments (G.W.C., unpublished data). In another
study, Filamin A, Hop, and the coatomer subunits (b, d, and g)
were identified as PARP substrates, and these are all CFTR inter-
actome members (Isabelle et al., 2010; Wang et al., 2006).
Hence, this may suggest a possible mechanism in which COP
vesicle formation and protein loading for transport to the plasma
membrane is regulated via PARP activity. Another possible
method of action revolves around the ezrin-radixin-moesin
complex; these are scaffolding proteins linked to proper CFTR
trafficking and localization in the plasma membrane (Huang
et al., 2003). All three proteins are targets for ribosylation (Mar-
esso et al., 2004), and itmay be that their ribosylation state needs1296 Chemistry & Biology 19, 1288–1299, October 26, 2012 ª2012 Eto be altered in order for F508del-CFTR to be trafficked to the cell
surface.
F508del-CFTR correction levels varied from 45% of wild-type
in the cell-surface assay in BHK cells (Figure 1) to 9% of wild-
type function in in vivo mouse assays and down to 2.5% in an
ex vivo mouse assay (Figure 3F). The ex vivo assay may be
due to the short incubation with latonduine (4 hr), especially
given the fact that the in vivo salivary assay result is the largest
response of any compound tested in this assay (Figure 3G).
The level of correction that is needed for clinical benefit is not
established, but estimates range from 10% of wild-type CFTR
(Farmen et al., 2005) up to 25% (Zhang et al., 2009). Higher levels
of correction can be achieved by selection of compounds that
act on different targets and pathways (Rabeh et al., 2012; Jansen
et al., 2009).
We show that compounds in combination have an additive or
synergistic effect in correction of F508del-CFTR. The identifica-
tion of cellular targets of correctors found in cell-based screens
will accelerate SAR development. Further target identification is
the first step in determining their mechanism of action as well as
providing the basis for a rational choice of correctors for com-
bination therapies.
SIGNIFICANCE
The most common mutation that causes cystic fibrosis is
the deletion of phenylalanine at position 508 of CFTR. The
mutant protein is retained in the ER and subjected to ER-
associated degradation. F508del-CFTR protein trafficking
can be partially restored by the use of a variety of com-
pounds, but the targets of these are mostly unknown.
F508del-CFTR trafficking correctors tend to come from
commercially available compound libraries. To explore
chemical space, we screened a tropical marine sponge
extract collection and used cell-based bioassay-guided
fractionation. The corrector family identified was the laton-
duines. Using a biotinylated azido-latonduine derivative,
we identified the specific cellular target as a member of
the PARP protein family, specifically PARP-3. Using purified
PARP family members, we confirmed that PARP-3 is the
target. First, by increasing PARP activity using peroxynitrite,
we inhibited CFTR correction, and second, the reduction of
PARP-3 expression by siRNA reduces the amount of laton-
duine necessary for CFTR rescue. We show that latonduine
works in combination with other correctors to give in-
creased levels of rescue. We identify latonduines as a com-
pound class that modulates protein misfolding and also
identify a pathway with a protein target set for the develop-
ment of correctors.
EXPERIMENTAL PROCEDURES
HTS Protocol
The screen assay was undertaken as previously reported using BHK cells that
stably express F508del-CFTR bearing three tandem hemagglutinin-epitope
tags (3HA) in the fourth extracellular loop (Carlile et al., 2007). Extracts were
initially tested at 10 mg for 24 hr prior to fixation (4% paraformaldehyde) and
immunofluorescence. Surface CFTRwas identified using amousemonoclonal
anti-HA antibody (Sigma-Aldrich; H9658). Hits are defined as fractions that
consistently gave signals that were three standard deviations above untreatedlsevier Ltd All rights reserved
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study and fractionation.
Western Blots
Immunoblotting was performed as previously published (Carlile et al., 2007);
for CFTR expressed in BHK cells the anti-CFTR antibody used was the mouse
monoclonal anti-CFTR antibody 24-1 (R&D Systems; MAB25031), and for
CFTR expressed in CFBE cells a mouse monoclonal antibody raised against
the CFTR R domain was used (G.W.C., unpublished data). To visualize
PARP-1 expression, the mouse monoclonal anti-PARP-1 (f-2) antibody (Santa
Cruz Biotechnology; Sc-8007) was used. Each CFTR protein glycoform level
was estimated by densitometry using the ImageJ program. The values
reported are expressed as means (n = 3).
Immunofluorescence
Immunofluorescencewas carried out as previously reported utilizing BHK cells
expressing F508del-CFTR (Carlile et al., 2007). The anti-CFTR antibody used
was the mouse monoclonal anti-CFTR antibody 24-1 (see Western Blots).
Analysis was done using the ImageJ system using 200 cells per sample in
six fields. The pixels per cell designation refers to the number of pixels of
CFTR stain that overlaps with the cell-surface marker for each cell in
a treatment.
Iodide Efflux Assay
Iodide efflux assays with stably transfected BHK or CFBE41o cells each
expressing either wild-type CFTR or F508del-CFTRwere performed according
to publishedmethods (Robert et al., 2010). CFTR-mediated iodide release was
stimulated with 10 mM forskolin and 50 mM genistein at room temperature.
Values reported are means ± SEM (n = 3). Data were compared by paired
t test using Prism (GraphPad).
Murine Experiments
Compounds were tested both ex vivo and in vivo using homozygous F508del-
CFTR mutant mice and wild-type littermate controls derived from a congenic
FVB strain (French et al., 1996). Mice were genotyped by standard PCR
methods using DNA isolated from mouse tails. All procedures followed
Canadian Institutes of Health Research rules and were approved by the faculty
Animal Care Committee.
Ex Vivo Experiments
Latonduine was tested ex vivo using ileum from 14- to 17-week-old homozy-
gous F508del-CFTR mice (30–34 g) as described previously. Each piece of
ileum was measured at time 0 and exposed to 10 mM latonduine for 4 hr,
and then the changes in short-circuit current across a plasma membrane
(Isc) response to forskolin + genistein was measured again in an Ussing
chamber (Robert et al., 2010). Tissue viability was confirmed by adding
10 mM glucose to stimulate electrogenic Na+-glucose cotransport. Results
are expressed as the mean (SEM of n pieces of ileum from N mice).
In Vivo Experiments
The procedure followedwas the same as those previously published (Best and
Quinton, 2005; Sampson et al., 2011). Homozygous F508del-CFTR and
wild-type mice (10–12 weeks old and 20–25 g) were fed once a day by gavage
with latonduine (50 mg/kg) for 2 days prior to experimentation. The rate of
salivary secretion per min and total amounts were normalized to the mass of
the mouse. Results are expressed as the mean (SEM of mice).
Latonduine Pull-Down Studies
Biotinylated Latonduine Pull-Down
Briefly, confluent CFBE41o cells expressing F508del-CFTR were washed in
buffer B (25 mM HEPES, 115 mM potassium acetate, 2.5 mM magnesium
chloride, and protease inhibitors; Roche) and harvested. The cells were placed
in buffer B+ (buffer B with 1% Triton X-100) and incubated 30 min on ice with
brief vortexing to lyse the cells. After centrifugation (10,0003 g for 10 min), the
supernatant collected was designated the cell lysate.
The protein concentration was adjusted to 1.2–1.4 mg/ml with buffer B+.
The lysate was precleared (4C) using beads (Dynal streptavidin M-280) (previ-
ously incubated in a biotin solution) for 1 hr and then removed. Biotin-labeledChemistry & Biology 19, 1288–1latonduine A (5 pmol) (Supplemental Experimental Procedures) and beads
(Dynal streptavidin M-280) were added and incubated for 3 hr at 4C. The
beads were collected and the supernatant was removed. The beads were
washed three times with buffer B (with 0.2% Triton X-100). The samples
were then resolved by SDS-PAGE and visualized by Coomassie blue stain.
Photoactivation and ‘‘Click Chemistry’’: Pull-Down
of Latonduine-Interacting Proteins
CFBE41o cell lysate was prepared as described above, and the protein
was assayed, adjusted to 2 mg/ml and precleared with Dynal beads
(M-280). The supernatant was collected and incubated with azido-latonduine
(see Supplemental Experimental Procedures) (1 hr at 4C), and then exposed
to UV light (365 nm) at a 5 cm distance for 1 hr. The click chemistry reaction
was performed as previously described (Tantama et al., 2008) (see Supple-
mental Experimental Procedures). After the click chemistry, Dynal (M-280)
magnetic beads were added and incubated for 1 hr and processed for mass
spectrometry (Jiang et al., 2010).
Mass Spectrometry
After separation by SDS-PAGE and total protein staining with Coomassie blue,
bands were excised and subjected to in-gel tryptic digestion as described
previously (Bhangoo et al., 2007). Mass spectra were compared to biotinylated
bead control lanes, and only proteins unique to the sample lane were consid-
ered (Figure S1). Peptides were analyzed by C18 reverse-phase separation
followed by ion-trap liquid chromatography-tandem mass spectrometry on
a Daltonics Esquire HCT instrument (Bruker). Spectra were searched against
mammalian sequences in the National Center for Biotechnology Information
database using the Mascot search engine (Matrix Science).
Latonduines
The isolation and structure elucidation of latonduine A and the methyl and
ethyl esters of latonduine B have been described elsewhere (Linington et al.,
2003).
RNA Extraction and Quantitative Real-Time RT-PCR
This was performed as previously described (Robert et al., 2008).
CFBE41o cells were treated with latonduine (10 mM) or 0.1% DMSO
(untreated control) for 48 hr. RNA was extracted with TRIzol (Invitrogen)
according to the manufacturer’s instructions. Relative CFTR expression
was quantified using a standard curve that spanned six logs, using cDNA
from untreated CFBE41o cells reverse-transcribed under the same condi-
tions. Standard curves were included in all experiments. Primer efficiency
was nearly 100% for all pairs.
PARP Enzymatic Assays
The HT Universal Chemiluminescent PARP assay kit with histone-coated strip
wells (Trevigen) was used per the manufacturer’s instructions to test PARP
inhibition by latonduine. Experiments were completed in triplicate and
analyzed using Prism (GraphPad).
The PARP in vivo pharmacodynamic assay (Trevigen; 4510-096-K) was
used to measure PARP activity in cell lysates. BHK cells were grown until
80% confluent and treated for the requisite time. Experiments were performed
in triplicate and analyzed using Prism (GraphPad).
High-Throughput FACS Assay
siRNA Treatment
HEK293 Flp-In T-REx cells were tetracycline (1 mg/ml) (Invitrogen) induced
for 24 hr to induce CFTR3HA WT or F508del expression. PARP-1,
PARP-3, PARP-5a, and nontargeting siRNAs were arrayed into a 96-well
plate. Transduction followed the manufacturer’s instructions, with T-REx
CFTR WT 3HA cells added to the plate as controls. The next day the media
were exchanged for media containing antibiotics, tetracycline, and laton-
duine or DMSO.
FACSArray Staining
Twenty-four hours later, the cells were trypsinized and transferred to a 96-well
plate. Cells were stained with the viability dye 7AAD (Invitrogen) for 5 min,
washed in PBS, and then fixedwith 4%paraformaldehyde (Sigma) and stained
(Supplemental Experimental Procedures). Ten thousand events were acquired
on a flow cytometer. Voltages were set for the phycoerythrin and 7AAD signals
using single-staining and isotype controls. Experiments were in triplicate and
analyzed using FlowJo (Tree Star).299, October 26, 2012 ª2012 Elsevier Ltd All rights reserved 1297
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